摘要
Abstract
OBJECTIVE:To observe the efficacy and safety of mesalazine combined with bifidobacterium tetravaccine(live)in the treatment of ulcerative colitis(UC). METHODS:83 UC patients were tandomly divided into control group(42 cases)and test group (41 cases). Control group was orally given 1.0 g Mesalazine enteric-coated tablet,4 times a day;test group was additionally given 1.5 g Bifidobacterium tetravaccine tablet(live),3 times a day. The treatment course fr both group was 6 weeks. The clinical efficacy,and serum high sensitivity C-reactive protein(hs-CRP),interleukin(IL)-4,IL-8 levels before and after treatment and the incidence of ad-verse reactions in 2 groups were observed. RESULTS:After treatment,serum hs-CRP and IL-8 in 2 groups were significantly lower than before,and test group was lower than control group;serum IL-4 level was significantly higher than before,and test group was higher than control group,the differences were statistically significant(P<0.05 or P<0.01). Total effective rate in test group was sig-nificantly higher than control group,the difference was statistically significant(P<0.05). And there was no significant difference in the incidence of adverse reactions (P>0.05). CONCLUSIONS:Mesalazine combined with bifidobacterium tetravaccine (live) is more effective than mesalazine alone UC,with similar safety.关键词
溃疡性结肠炎/美沙拉嗪/双歧杆菌四联活菌/疗效/安全性Key words
Ulcerative colitis/Mesalazine/Bifidobacterium tetravaccine/Efficacy/Safety分类
医药卫生
